<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/lonza-commercial-spray-drying-facility-oregon-sdd-manufacturing</loc>
    <lastmod>2026-09-11T13:51:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T00:00:00+05:30</news:publication_date>
      <news:title>Lonza Builds Oregon Spray-Drying Facility To Expand SDD Capacity</news:title>
      <news:keywords>Lonza</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b2eccf0e-ce5f-4e49-8a3b-82df5afa3f1e/bc6bbde4-0588-43e3-905b-add9fe7eb8b0.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/nicox-nmpa-acceptance-ncx-470-nda-china-review</loc>
    <lastmod>2026-09-11T13:47:12+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T00:00:00+05:30</news:publication_date>
      <news:title>China NMPA Accepts Nicox NCX 470 NDA; Decision In 18 Months</news:title>
      <news:keywords>China NMPA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b2eccf0e-ce5f-4e49-8a3b-82df5afa3f1e/01044b9a-35e6-4a3e-a60d-447e1513c34c.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/axcelead-hitaka-glp-1-rodent-nausea-model-jsso-jsto-2026</loc>
    <lastmod>2026-09-11T10:37:33+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T00:00:00+05:30</news:publication_date>
      <news:title>Hitaka To Present Axcelead GLP-1 Rodent Nausea Data At Obesity 26</news:title>
      <news:keywords>Hitaka</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://axcelead-us.com/wp-content/uploads/2025/04/hitaka.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/xortx-initiates-gmp-manufacturing-xorlo-clinical-nda-dossier</loc>
    <lastmod>2026-09-11T13:44:14+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T00:00:00+05:30</news:publication_date>
      <news:title>XORTX Initiates GMP Manufacturing Of XORLO™ For Dual Dossier</news:title>
      <news:keywords>XORTX</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/xortx-initiates-gmp-manufacturing-xorlo-clinical20260911134359.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-nih-cdc-workshop-valley-fever-vaccine-regulatory-pathway-2024</loc>
    <lastmod>2026-09-11T13:39:43+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T00:00:00+05:30</news:publication_date>
      <news:title>FDA, NIH &amp; CDC Host Workshop On Valley Fever Vaccine Pathway</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-nih-cdc-workshop-valley-fever-vaccine-pathway20260911133930.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/medical-action-industries-class-i-correction-epidural-kits-huons-sterility-cascade</loc>
    <lastmod>2026-09-11T10:37:39+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T00:00:00+05:30</news:publication_date>
      <news:title>Medical Action Recalls Epidural Kits Over Sterility Risk</news:title>
      <news:keywords>Medical Action</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/a72bc3d0-b709-497c-98a4-e494e7607feb/53139a57-2b33-4fb4-8ce6-45e5bb581c50.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/roche-fda-approval-cobas-malaria-nat-donor-screening</loc>
    <lastmod>2026-09-11T13:25:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-11T00:00:00+05:30</news:publication_date>
      <news:title>Roche Cobas Malaria Test Gets FDA Approval For Donor Screening</news:title>
      <news:keywords>Roche</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-fda-approval-cobas-malaria-nat-screening20260911132537.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cosette-pharmaceuticals-appoints-andrew-adams-vp-supply-chain-sourcing</loc>
    <lastmod>2026-09-11T10:49:50+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>Cosette Pharmaceuticals Appoints Andrew Adams as Vice President of Supply Chain and Sourcing</news:title>
      <news:keywords>Cosette</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/cosette-pharmaceuticals-appoints-andrew-adams-vp20260911104939.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-atogepant-phase-3-luna-menstrual-migraine-results</loc>
    <lastmod>2026-09-11T10:43:09+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie Achieves Phase 3 Primary and All Secondary Endpoints for Atogepant in Menstrual Migraine</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-atogepant-phase-3-luna-menstrual-migraine20260911104252.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-removes-paba-trolamine-salicylate-otc-sunscreen-monograph-2026</loc>
    <lastmod>2026-09-11T10:40:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>FDA Removes PABA and Trolamine Salicylate from OTC Sunscreen Monograph in September 2026 Final Order</news:title>
      
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-removes-paba-trolamine-sunscreen-monograph20260911103919.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/roche-fda-priority-review-enspryng-sbla-mogad-january-2027</loc>
    <lastmod>2026-09-11T10:36:28+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>Roche Gains FDA Priority Review for Enspryng sBLA in MOGAD with Decision Due January 2027</news:title>
      <news:keywords>Roche</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-fda-priority-review-enspryng-mogad20260911103615.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/medicus-pharma-skinject-phase-2-csr-200mcg-dose-basal-cell-carcinoma</loc>
    <lastmod>2026-09-11T10:31:18+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>Medicus Pharma Identifies 200 µg D-MNA Dose as Lead in Phase 2 SkinJect CSR for Basal Cell Carcinoma</news:title>
      <news:keywords>Medicus</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/medicus-pharma-skinject-phase-2-basal-cell-carcinoma20260911103108.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/sarborg-quantum-computing-signature-intelligence-neuropsychiatric-drug-discovery</loc>
    <lastmod>2026-09-11T10:22:47+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>Sarborg Applies Quantum Computing and Signature Intelligence Models to Neuropsychiatric Drug Discovery</news:title>
      <news:keywords>Sarborg</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/sarborg-quantum-computing-neuropsychiatric-drug-discovery20260911102237.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ritedose-appoints-carolyn-berg-vice-president-strategic-growth</loc>
    <lastmod>2026-09-10T22:31:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>Ritedose Appoints Carolyn Berg as Vice President of Strategic Growth in Sterile BFS Expansion</news:title>
      <news:keywords>Ritedose</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml.globenewswire.com/Resource/Download/1d5f4368-063b-4fb9-9364-e6cf4fe049c8</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-ich-m3r2-nonclinical-safety-studies-clinical-trial-authorization</loc>
    <lastmod>2026-09-10T13:06:34+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>FDA Resurfaces ICH M3(R2) Guidance on Nonclinical Safety Studies</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-ich-m3r2-nonclinical-safety-studies20260910130628.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/novo-nordisk-fda-approval-rebinyn-recombinant-glycopegylated-factor-ix-hemophilia-b</loc>
    <lastmod>2026-09-10T13:11:14+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>Novo Nordisk Rebinyn Obtains Fda Approvals For Hemophilia B Cases</news:title>
      <news:keywords>Novo Nordisk</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novo-nordisk-fda-approval-rebinyn-hemophilia-b20260910131100.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-otat-gene-therapy-cmc-town-hall-series-advanced-therapy-manufacturers</loc>
    <lastmod>2026-09-10T10:29:37+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-10T00:00:00+05:30</news:publication_date>
      <news:title>FDA OTAT Launches Gene Therapy CMC Town Hall Series</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/471f2524-97bb-4616-9ac3-71e7ca1f298d/7ada22f5-ddf1-4307-9543-08d93876e8a8.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/proqr-therapeutics-doses-first-participant-phase-1-ax-0811-rna-editing</loc>
    <lastmod>2026-09-10T13:24:34+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>ProQR Therapeutics Doses First Participant in Phase 1 Study of AI-Discovered RNA Editing Candidate AX-0811</news:title>
      <news:keywords>ProQR</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/proqr-therapeutics-phase-1-ax-0811-rna-editing20260910132424.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/propanc-biopharma-phase-1b-first-in-human-prp-february-2027</loc>
    <lastmod>2026-09-10T13:26:35+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Propanc Biopharma Targets February 2027 First-in-Human Phase 1b Study of PRP in Solid Tumors</news:title>
      <news:keywords>Propanc</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/propanc-biopharma-phase-1b-prp-202720260910132631.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cellipont-bioservices-xiogenix-fill-finish-white-paper-cell-therapy-manufacturing</loc>
    <lastmod>2026-09-10T13:33:45+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Cellipont Bioservices and Xiogenix Publish Fill-Finish White Paper for Scalable Cell Therapy Manufacturing</news:title>
      <news:keywords>Cellipont</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/cellipont-bioservices-xiogenix-fill-finish-white-paper20260910133334.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/bayer-fda-accelerated-approval-sevabertinib-her2-mutant-nsclc-first-line</loc>
    <lastmod>2026-09-10T13:38:25+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Bayer Gains FDA Accelerated Approval for Sevabertinib in First-Line HER2-Mutant NSCLC</news:title>
      <news:keywords>Bayer</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bayer-fda-accelerated-approval-sevabertinib-nsclc20260910133808.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cdsco-risk-based-drug-regulation-compliance-burden-2026</loc>
    <lastmod>2026-09-10T13:43:35+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>CDSCO Shifts To Risk-Based Drug Approvals To Ease Compliance</news:title>
      <news:keywords>CDSCO</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/cdsco-risk-based-drug-regulation-compliance20260910134329.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/just-evotec-biologics-jst-018-orthopoxvirus-phase-1-dow-contract</loc>
    <lastmod>2026-09-10T13:51:26+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Just Evotec Advances JST-018 Orthopoxvirus Cocktail To Phase 1</news:title>
      <news:keywords>Just Evotec</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/just-evotec-biologics-jst-018-orthopoxvirus20260910135115.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/probiogen-transgene-expand-virus-based-therapy-manufacturing-collaboration</loc>
    <lastmod>2026-09-10T13:56:46+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>ProBioGen &amp; Transgene Expand Virus-Based Therapy Manufacturing</news:title>
      <news:keywords>ProBioGen</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/probiogen-transgene-virus-based-therapy-manufacturing20260910135634.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/onyx-scientific-expands-uk-gmp-api-capacity-15-million-investment</loc>
    <lastmod>2026-09-10T14:06:56+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Onyx Scientific Expands UK API Capacity With £1.5M Investment</news:title>
      <news:keywords>Onyx</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/onyx-scientific-expands-uk-gmp-api-capacity20260910140646.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/rezubio-doses-first-patients-phase-i-trial-inhaled-rz-520</loc>
    <lastmod>2026-09-10T14:11:26+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Rezubio Begins Phase I Trial Of Inhaled Respiratory Drug RZ-520</news:title>
      <news:keywords>Rezubio</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/rezubio-phase-i-inhaled-rz-52020260910141122.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/elix-axcelead-ddp-collaborative-research-agreement-targeted-protein-degraders</loc>
    <lastmod>2026-09-10T14:19:07+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Elix &amp; Axcelead Partner to Accelerate Protein Degrader Discovery</news:title>
      <news:keywords>Elix</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/elix-axcelead-collaboration-targeted-protein-degraders20260910141858.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/neurizon-appoints-dr-chris-bremer-ceo</loc>
    <lastmod>2026-09-10T14:14:37+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Neurizon Appoints Dr. Chris Bremer As CEO To Lead Strategy</news:title>
      <news:keywords>Neurizon</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/neurizon-appoints-dr-chris-bremer-ceo20260910141423.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/inhibitor-therapeutics-itraconazole-bccns-revised-fda-regulatory-strategy</loc>
    <lastmod>2026-09-10T14:23:57+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Inhibitor Therapeutics Updates FDA Strategy for Itraconazole</news:title>
      <news:keywords>Inhibitor Therapeutics</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/inhibitor-therapeutics-itraconazole-bccns-fda-strategy20260910142344.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/assembly-biosciences-exercises-us-profit-share-option-gilead-hsv-helicase-primase-inhibitor</loc>
    <lastmod>2026-09-10T14:41:08+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Assembly Bio Exercises 40% US Profit Option With Gilead On HSV</news:title>
      <news:keywords>Assembly Bio</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/assembly-biosciences-profit-share-gilead-hsv-inhibitor20260910144100.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/inventiva-presents-five-lanifibranor-abstracts-paris-mash-2026</loc>
    <lastmod>2026-09-09T12:15:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>Inventiva Presents Five Lanifibranor Abstracts At Paris MASH 2026</news:title>
      <news:keywords>Inventiva</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/8a472dbf-aab6-4299-ace8-f116236f4c33/8d23e27e-0d1c-4f01-b926-d68c81a08696.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-ddt-qualification-metrics-update-september-2026</loc>
    <lastmod>2026-09-09T12:13:22+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>FDA Updates DDT Metrics: 160 Projects Active As Of July 2026</news:title>
      <news:keywords>FDA Updates</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/8a472dbf-aab6-4299-ace8-f116236f4c33/e23d85ff-56de-4ba0-b7d1-0d515985af3b.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-cber-blood-products-approval-pathways-bla-nda-pma-510k</loc>
    <lastmod>2026-09-09T12:18:17+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>FDA Maps 4 Approval Pathways For Blood Products</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/4dbd3692-e5b4-44a9-99ce-ab8b6ef59e9f/0a872d01-50f4-4e09-b8f9-6ffae647b85e.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-clarifies-cber-jurisdiction-nda-anda-blood-products</loc>
    <lastmod>2026-09-09T12:21:05+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>FDA Clarifies CBER Control Over Blood NDA And ANDA Paths</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/4dbd3692-e5b4-44a9-99ce-ab8b6ef59e9f/45793206-9fe9-47a0-9e99-064c0bb1560d.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-updates-general-biologics-guidance-library-cmc-gmp-documents</loc>
    <lastmod>2026-09-09T12:23:39+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-09-09T00:00:00+05:30</news:publication_date>
      <news:title>FDA Updates Biologics Library With CMC And GMP Reference Docs</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/4dbd3692-e5b4-44a9-99ce-ab8b6ef59e9f/64420afd-aa9d-4e9f-bd65-b5747e89bf14.png</image:loc>
    </image:image>
  </url>
</urlset>